Eli Lilly and Company (LLY)

Eli Lilly and Company (LLY) is a healthcare company (drug manufacturers - general) based in the United States. The share price is $1,415.55, down 1.13% on the day, which values the company at $1.26T. Price as of 17 Nov 2026, 17:10 UTC, from Yahoo Finance.

Key facts

Share price
$1,415.55−1.13% today
Market value
$1.26T
P/E ratio
45.9×last 12 months
Forward P/E
27.9×
Dividend yield
0.47%
Funk Score
70/100
Against its own history
Well above its usual priceusual price $324.25
200-week average
$802.9276% above

Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.

Eli Lilly and Company in more detail

LLY trades at 45.9× its last twelve months' earnings, 27.9× next year's expected earnings, 14.6× sales. Measured against its own history, the price is 337% above what its usual multiples would imply ($324.25) — well above its usual price. It sits 76% above its 200-week average of $802.92.

Over the last five fiscal years Eli Lilly and Company has compounded revenue 21.6% a year, earnings per share 27.6% a year. Its Funk Score is 70 out of 100 (financial strength 6.8, profitability 8.6, growth 10.0, value 2.7, each out of 10).

In its favour: Altman Z in the safe zone; Strong Piotroski score.

28 of the superinvestors tracked here hold LLY, including Primecap team (6.5% of the portfolio), Polen Capital team (4.6% of the portfolio), Jensen team (4.0% of the portfolio).

Superinvestors holding LLY

28 of the investors tracked here report a position in their latest 13F filing.

Compare

Health Care companies of similar size

Side by side:LLY vs JNJ (Eli Lilly and Company vs Johnson & Johnson)LLY vs ABBV (Eli Lilly and Company vs AbbVie)LLY vs MRK (Eli Lilly and Company vs Merck & Co)LLY vs UNH (Eli Lilly and Company vs UnitedHealth Group)LLY vs NVS (Eli Lilly and Company vs Novartis)

All health care companies by market valueLargest companies in the United StatesAll stocks A–Z

Eli Lilly and Company (LLY): questions and answers

What is LLY's P/E ratio?

Eli Lilly and Company trades at 45.9× its last twelve months' earnings and 27.9× next year's expected earnings. At its fiscal year-ends over the past 16 years the P/E ranged from 7.7× to 100.5×, with a median of 29.7×.

What is LLY's PEG ratio?

Eli Lilly and Company's PEG ratio is 1.33 — its P/E divided by its expected earnings growth. Around 1 is the classic sign of a price that matches the growth; well above it means the growth is being paid for in advance.

What is Eli Lilly and Company's market cap?

Eli Lilly and Company is valued at $1.26T at a share price of $1,415.55.

Is LLY overvalued or undervalued?

Against its own history, LLY is well above its usual price: the price is 337% above the $324.25 implied by the median multiples it has traded at (price / earnings, price / sales, price / book). That compares the stock with its past; it does not say whether the business now deserves a higher or lower multiple.

Is LLY above its 200-week moving average?

Yes. LLY is 76.3% above its 200-week average of $802.92. Long-term investors watch that line because strong companies rarely trade below it for long.

How fast is Eli Lilly and Company growing?

Over the last five fiscal years Eli Lilly and Company's revenue grew 21.6% a year and its earnings per share 27.6% a year; over ten years revenue grew 12.6% a year.

Cite this page

Funkfolio, “Eli Lilly and Company (LLY) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/LLY

Underlying data: Yahoo Finance; company filings with the SEC.